RT Book, Section
A1 Dall’Era, Marc A.
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1193162674
T1 Renal Cell Carcinoma
T2 Current Medical Diagnosis & Treatment 2023
YR 2023
FD 2023
PB McGraw-Hill Education
PP New York, NY
SN 9781264687343
LK accessmedicine.mhmedical.com/content.aspx?aid=1193162674
RD 2024/04/23
AB Key  Clinical  Updates  in  Renal  Cell  CarcinomaFor  patients  with  von  Hippel-Lindau  disease  and  renal  cell  carcinoma,  belzutifan,  a  HIF2a  inhibitor,  leads  to  dramatic  size  reductions  in  both  renal  and  non-renal  neoplasms  and  offers  a  new  treatment  option.Pembrolizumab  is  FDA-approved  for  adjuvant  treatment  after  surgical  resection  of  renal  cell  carcinoma  in  patients  at  high  risk  for  disease  recurrence.The  SURTIME  randomized  trial  compared  immediate  versus  deferred  cytoreductive  nephrectomy  in  patients  with  metastatic  renal  cell  carcinoma  treated  with  sunitinib  and  showed  an  overall  survival  advantage  with  the  deferred  approach.  This  may  serve  to  identify  patients  who  respond  the  best  to  systemic  therapy  prior  to  undergoing  removal  of  the  primary  tumor.Bex  A  et  al.  JAMA  Oncol.  [PMID:  30543350]Jonasch  E  et  al.  N  Engl  J  Med.  [PMID:  34818478]Rini  BI  et  al;  KEYNOTE-426  Investigators.  N  Engl  J  Med.  [PMID:  30779529]